SEC Filing Summary
Filing identification: The supplied filing is Ambac Financial Group, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2021, not Octave Specialty Group Inc. The summary below reflects the filing text provided.
Business Context and Reporting Period
Ambac is a financial services holding company whose legacy financial guarantee businesses, Ambac Assurance Corporation and Ambac Assurance UK Limited, have been in runoff since 2008. The company is also developing specialty property and casualty program insurance through Everspan and managing general agency/underwriting operations through Xchange.
Everspan received an A- Financial Strength Rating from A.M. Best in February 2021 and launched its first insurance program in May 2021. The filing covers the three and six months ended June 30, 2021, compared with the corresponding 2020 periods. Dollar amounts are in millions unless otherwise stated.
Key Financial Metrics
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Total revenues | $49 | $75 | $178 | $6 |
| Net investment income | $42 | $52 | $91 | $31 |
| Net premiums earned | $11 | $11 | $25 | $21 |
| Net gains/(losses) on derivatives | $(11) | $2 | $14 | $(68) |
| Losses and loss expenses | $(26) | $16 | $(18) | $132 |
| Operating expenses | $28 | $21 | $62 | $44 |
| Interest expense | $50 | $58 | $100 | $122 |
| Net loss attributable to common stockholders | $(29) | $(35) | $(12) | $(315) |
| Loss per diluted share | $(0.63) | $(0.77) | $(0.54) | $(6.83) |
- Adjusted earnings: $(13), or $(0.30) per diluted share, in Q2 2021; $27, or $0.30 per diluted share, for the first six months of 2021. These are non-GAAP measures.
- Adjusted book value: $889, or $19.25 per share, at June 30, 2021, versus $919, or $20.05 per share, at December 31, 2020.
- Assets and equity: Total assets were $12,907, down from $13,220 at year-end 2020. Total stockholders’ equity was $1,123, down from $1,140.
- Investments: Total investments were $3,447, including $2,253 of fixed maturity securities, $416 of short-term investments and $657 of other investments.
- Liquidity: Cash, cash equivalents and restricted cash totaled $32 at June 30, 2021, compared with $34 at June 30, 2020. AFG’s net assets excluding equity investments in subsidiaries were $281, including $128 of cash and short-term investments.
- Cash flow: Six-month operating cash flow was $(83), investing cash flow was $187, financing cash flow was $(107), and net cash flow was $(4).
- Debt: Consolidated long-term debt was $2,671 at June 30, 2021, versus $2,739 at December 31, 2020. Accrued interest payable was $532. Total consolidated VIE liabilities included $4,434 of long-term debt and $1,800 of derivative liabilities.
- Insurance exposure: Financial guarantee net par outstanding declined to $30,234 from $33,888 at year-end 2020. Adversely classified credits declined to $6,924 from $8,458, and watch-list credits declined to $4,213 from $4,720.
Material Changes Versus Prior Comparable Period
- First-half 2021 net loss attributable to common stockholders improved substantially to $(12) from $(315), primarily reflecting lower loss expenses, improved derivative results, higher investment income and debt-extinguishment gains.
- Losses and loss expenses shifted to an $18 benefit in the first half of 2021 from $132 of expense in the prior-year period. The 2021 benefit primarily reflected favorable development in structured finance and prior-year claims, partially offset by public finance credit losses.
- Derivative results improved to a $14 gain from a $68 loss, while Q2 2021 produced an $11 loss compared with a $2 gain in Q2 2020 due primarily to lower forward interest rates and carrying costs.
- First-half net investment income increased by $60 to $91, mainly because pooled-fund performance and other investment results were substantially better than in the COVID-19-affected first half of 2020. Q2 investment income declined by $10 because the comparison period benefited from a strong market recovery.
- Operating expenses increased to $62 from $44 for the first half, reflecting additional staffing, incentive compensation, Xchange-related producer commissions, software and legal costs, and costs associated with debt exchanges.
- Interest expense declined to $100 from $122, primarily because of lower surplus-note discount accretion, optional LSNI Ambac Note redemptions and lower rate resets.
- Ambac completed risk-reduction transactions totaling $666 in Q2 and $2,040 for the first six months, including quota-share reinsurance, refinancings and commutations.
- AAC exchanged or acquired all outstanding junior surplus notes in the first quarter. The transactions generated a $33 gain on debt extinguishment and reduced debt by approximately $71.
Guidance, Outlook, Risks and Unusual Items
- No formal earnings or revenue guidance is provided. Management’s stated strategy is to run off legacy financial guarantees, reduce risk and liabilities, pursue recoveries, rationalize capital and invest selectively in specialty P&C and MGA/U businesses.
- On July 6, 2021, newly formed Sitka Holdings issued $1,175 of senior secured notes due 2026 at LIBOR plus 4.5%. Proceeds were used to fund the redemption of the LSNI Secured Notes; the remaining redemption amount was funded from other liquidity sources. This subsequent event was not reflected in the June 30 balance sheet.
- AAC’s payment of surplus-note principal and interest requires approval from the Wisconsin Office of the Commissioner of Insurance. OCI declined AAC’s request for the scheduled June 7, 2021 payment. Third-party surplus-note principal and accrued interest totaled $1,414 as of February 11, 2021, and accrued unpaid interest was $532 at June 30, 2021.
- AFG expects little or no near-term dividend capacity from AAC. Everspan also lacked sufficient earned surplus to pay ordinary dividends. This increases reliance on AFG-level liquidity, cost reimbursements and distributions from Xchange.
- Ambac UK remained deficient under Solvency II requirements by £20 at June 30, 2021, improved from a £72 deficiency at December 31, 2020. Management reported ongoing discussions with regulators and limited options for addressing the shortfall.
- Puerto Rico remains a major risk. Net par exposure was $1,067, and policy payments and recoveries depend on the confirmation and implementation of restructuring plans, litigation outcomes, fiscal performance and contingent value instruments.
- The filing estimates a possible increase in public-finance loss reserves of approximately $545 under stress scenarios. A loss of that amount would reduce stockholders’ equity from $1,123 to approximately $578; losses could exceed the estimate.
- Ambac recorded $1,741 of gross RMBS representation-and-warranty subrogation recoveries, or $1,715 net of reinsurance. If these recoveries were not realized, stockholders’ equity would decrease from $1,123 to approximately $(592).
- COVID-19, interest rates, credit spreads, foreign exchange, litigation, reinsurer performance, collateral requirements and the LIBOR transition remain material sources of uncertainty.
- AFG contributed approximately $82 of capital to Everspan during the first half of 2021 and made minority investments in insurance-related and insurtech businesses. Proposed acquisitions of insurance shell companies remained subject to regulatory approval.
Most Important Facts for Investors to Verify
- Confirm that the filing issuer is Ambac Financial Group, Inc., not Octave Specialty Group Inc., and verify the intended company and filing period.
- Review AAC’s statutory capital, surplus-note payment restrictions and the potential effect of further reserve development on regulatory solvency.
- Assess the collectability, timing and legal risks surrounding the $1,715 net RMBS recovery asset.
- Evaluate Puerto Rico restructuring outcomes, including the Seventh Amended Plan of Adjustment and the value of proposed contingent value instruments.
- Reconcile the June 30 debt and liquidity position with the July 6 Sitka refinancing and LSNI redemption.
- Monitor Ambac UK’s remaining Solvency II capital deficiency and the outcome of regulatory discussions.
- Distinguish GAAP losses from non-GAAP adjusted earnings and adjusted book value, and assess the sensitivity of results to investment markets and derivative valuations.